Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer.

Banham D, Roder D, Keefe D, Farshid G, Eckert M, Howard N, Canuto K, Brown A; CanDAD Aboriginal Community Reference Group and other CanDAD investigators.

BMC Health Serv Res. 2019 Jun 14;19(1):387. doi: 10.1186/s12913-019-4147-5.

2.

ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.

Farshid G, Bilous M, Morey A, Fox S, Lakhani S, Loi S, Bell R, Spillane A.

Pathology. 2019 Jun;51(4):345-348. doi: 10.1016/j.pathol.2019.02.004. Epub 2019 May 7.

PMID:
31076089
3.

Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis.

Farshid G, Buckley E.

Breast Cancer Res Treat. 2019 Feb;174(1):165-177. doi: 10.1007/s10549-018-5040-3. Epub 2018 Nov 20.

PMID:
30460464
4.

Epithelioid myxofibrosarcoma developing at the injection site of Adalimumab therapy for psoriatic synovitis.

Farshid G, Prowse P, True B.

Eur J Rheumatol. 2018 Jul;5(2):131-134. doi: 10.5152/eurjrheum.2017.17083. Epub 2017 Dec 7.

5.

Molecular subtypes of screen-detected breast cancer.

Farshid G, Walters D.

Breast Cancer Res Treat. 2018 Nov;172(1):191-199. doi: 10.1007/s10549-018-4899-3. Epub 2018 Jul 25.

PMID:
30046938
6.

Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer.

Elmadahm A, Lord SJ, Hudson HM, Lee CK, Buizen L, Farshid G, Gebski VJ, Gill PG.

Breast. 2018 Oct;41:82-88. doi: 10.1016/j.breast.2018.05.011. Epub 2018 Jun 26.

PMID:
30007272
7.

Routine reporting of mammographic density from screening mammograms.

Farshid G.

ANZ J Surg. 2017 Dec;87(12):965-967. doi: 10.1111/ans.14179. No abstract available. Erratum in: ANZ J Surg. 2018 Apr;88(4):388.

PMID:
29205822
9.

Female breast cancer management and survival: The experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly.

Roder D, Farshid G, Kollias J, Koczwara B, Karapetis C, Adams J, Joshi R, Keefe D, Miller C, Powell K, Fusco K, Eckert M, Buckley E, Beckmann K, Price T.

J Eval Clin Pract. 2017 Dec;23(6):1433-1443. doi: 10.1111/jep.12819. Epub 2017 Oct 8.

PMID:
28990314
10.

HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program.

Kumarasinghe MP, Morey A, Bilous M, Farshid G, Francis G, Lampe G, McCue G, Von Neumann-Cosel V, Fox SB.

Pathology. 2017 Oct;49(6):575-581. doi: 10.1016/j.pathol.2017.05.009. Epub 2017 Aug 18.

PMID:
28823752
11.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

12.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

13.

Patterns of head and neck sarcoma in Australia.

Woods RH, Potter JA, Reid JL, Louise J, Bessen T, Farshid G, Neuhaus SJ.

ANZ J Surg. 2018 Sep;88(9):901-906. doi: 10.1111/ans.14018. Epub 2017 May 16.

PMID:
28512869
14.

Disparities in cancer stage at diagnosis and survival of Aboriginal and non-Aboriginal South Australians.

Banham D, Roder D, Keefe D, Farshid G, Eckert M, Cargo M, Brown A; CanDAD Aboriginal Community Reference Group and other CanDAD investigators.

Cancer Epidemiol. 2017 Jun;48:131-139. doi: 10.1016/j.canep.2017.04.013. Epub 2017 May 13.

PMID:
28511150
15.

Assessing impact of organised breast screening across small residential areas-development and internal validation of a prediction model.

Buckley E, Farshid G, Gill G, Kollias J, Koczwara B, Karapetis C, Adams J, Joshi R, Keefe D, Niyonsenga T, Powell K, Fusco K, Eckert M, Beckmann K, Roder D.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12673. Epub 2017 Mar 7.

PMID:
28271574
16.

Contemporary indications for diagnostic open biopsy in women assessed for screen-detected breast lesions: A ten-year, single institution series of 814 consecutive cases.

Farshid G, Gill PG.

Breast Cancer Res Treat. 2017 Feb;162(1):49-58. doi: 10.1007/s10549-016-4087-2. Epub 2017 Jan 6.

PMID:
28062979
17.

Breast cancer screening-opportunistic use of registry and linked screening data for local evaluation.

Roder D, Farshid G, Gill G, Kollias J, Koczwara B, Karapetis C, Adams J, Joshi R, Keefe D, Powell K, Fusco K, Eckert M, Buckley E, Beckmann K.

J Eval Clin Pract. 2017 Jun;23(3):508-516. doi: 10.1111/jep.12640. Epub 2016 Sep 22.

PMID:
27654906
18.

Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program.

Morey AL, Brown B, Farshid G, Fox SB, Francis GD, McCue G, von Neumann-Cosel V, Bilous M.

Pathology. 2016 Oct;48(6):535-42. doi: 10.1016/j.pathol.2016.05.007. Epub 2016 Aug 25.

PMID:
27567228
19.

The utility of linked cancer registry and health administration data for describing system-wide outcomes and research: a BreastScreen example.

Buckley ES, Sullivan T, Farshid G, Hiller JE, Roder DM.

J Eval Clin Pract. 2016 Oct;22(5):755-60. doi: 10.1111/jep.12536. Epub 2016 Mar 21.

PMID:
27001547
20.

Phyllodes tumours of the breast: a consensus review.

Tan BY, Acs G, Apple SK, Badve S, Bleiweiss IJ, Brogi E, Calvo JP, Dabbs DJ, Ellis IO, Eusebi V, Farshid G, Fox SB, Ichihara S, Lakhani SR, Rakha EA, Reis-Filho JS, Richardson AL, Sahin A, Schmitt FC, Schnitt SJ, Siziopikou KP, Soares FA, Tse GM, Vincent-Salomon A, Tan PH.

Histopathology. 2016 Jan;68(1):5-21. doi: 10.1111/his.12876. Review.

21.

Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH, Callen DF.

Sci Rep. 2015 Aug 27;5:13328. doi: 10.1038/srep13328. No abstract available.

22.

XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.

Pishas KI, Adwal A, Neuhaus SJ, Clayer MT, Farshid G, Staudacher AH, Callen DF.

Sci Rep. 2015 Jun 22;5:11465. doi: 10.1038/srep11465. Erratum in: Sci Rep. 2015;5:13328.

23.

The clinical utility of assessment of the axilla in women with suspicious screen detected breast lesions in the post Z0011 era.

Farshid G, Kollias J, Grantley Gill P.

Breast Cancer Res Treat. 2015 Jun;151(2):347-55. doi: 10.1007/s10549-015-3388-1. Epub 2015 Apr 23.

PMID:
25904216
24.

Estimates of over-diagnosis of breast cancer due to population-based mammography screening in South Australia after adjustment for lead time effects.

Beckmann K, Duffy SW, Lynch J, Hiller J, Farshid G, Roder D.

J Med Screen. 2015 Sep;22(3):127-35. doi: 10.1177/0969141315573978. Epub 2015 Apr 20.

PMID:
25896926
25.

Phyllodes tumour among participants in screening mammography.

Farshid G, Gill PG.

ANZ J Surg. 2017 Dec;87(12):E285-E292. doi: 10.1111/ans.13056. Epub 2015 Mar 19. Review.

PMID:
25786884
26.

Effectiveness of core biopsy for screen-detected breast lesions under 10 mm: implications for surgical management.

Farshid G, Downey P, Pieterse S, Gill PG.

ANZ J Surg. 2017 Sep;87(9):725-731. doi: 10.1111/ans.13037. Epub 2015 Mar 16.

PMID:
25776551
27.

The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking.

Belle L, Ali N, Lonic A, Li X, Paltridge JL, Roslan S, Herrmann D, Conway JR, Gehling FK, Bert AG, Crocker LA, Tsykin A, Farshid G, Goodall GJ, Timpson P, Daly RJ, Khew-Goodall Y.

Sci Signal. 2015 Feb 17;8(364):ra18. doi: 10.1126/scisignal.2005547.

PMID:
25690013
28.

Risk profile of breast cancer following atypical hyperplasia detected through organized screening.

Buckley E, Sullivan T, Farshid G, Hiller J, Roder D.

Breast. 2015 Jun;24(3):208-12. doi: 10.1016/j.breast.2015.01.006. Epub 2015 Feb 10.

PMID:
25681318
29.
30.

Case report: Cavitation of mesenteric lymph nodes as the presenting feature of coeliac disease.

Forrest CE, Masters V, Smith CL, Farshid G.

J Med Imaging Radiat Oncol. 2015 Aug;59(4):471-3. doi: 10.1111/1754-9485.12274. Epub 2015 Jan 15.

PMID:
25588513
31.

Multicentric myofibroblastic sarcoma.

Wechalekar MD, Ayres O, Farshid G, Clayer M, Cleland LG.

BMJ Case Rep. 2014 Nov 3;2014. pii: bcr2013201666. doi: 10.1136/bcr-2013-201666.

32.

Estimating over-diagnosis of breast cancer (authors' reply).

Beckmann K, Lynch J, Hiller J, Farshid G, Duffy S, Roder D.

Int J Cancer. 2015 May 15;136(10):2487. doi: 10.1002/ijc.29271. Epub 2014 Nov 18. No abstract available.

33.

Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors.

Lawton TJ, Acs G, Argani P, Farshid G, Gilcrease M, Goldstein N, Koerner F, Rowe JJ, Sanders M, Shah SS, Reynolds C.

Int J Surg Pathol. 2014 Dec;22(8):695-8. doi: 10.1177/1066896914548763. Epub 2014 Aug 26.

34.

A novel case-control design to estimate the extent of over-diagnosis of breast cancer due to organised population-based mammography screening.

Beckmann KR, Lynch JW, Hiller JE, Farshid G, Houssami N, Duffy SW, Roder DM.

Int J Cancer. 2015 Mar 15;136(6):1411-21. doi: 10.1002/ijc.29124. Epub 2014 Aug 18.

35.

Influence of service characteristics on high priority performance indicators and standards in the BreastScreen Australia program.

Roder DM, Ward GH, Farshid G, Gill PG; BreastScreen Australia National Quality Management Committee.

Asian Pac J Cancer Prev. 2014;15(14):5901-8.

36.

Influence of mammographic screening on breast cancer incidence trends in South Australia.

Beckmann KR, Roder DM, Hiller JE, Farshid G, Lynch JW.

Asian Pac J Cancer Prev. 2014;15(7):3105-12.

37.

Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.

Pishas KI, Neuhaus SJ, Clayer MT, Schreiber AW, Lawrence DM, Perugini M, Whitfield RJ, Farshid G, Manavis J, Chryssidis S, Mayo BJ, Haycox RC, Ho K, Brown MP, D'Andrea RJ, Evdokiou A, Thomas DM, Desai J, Callen DF, Neilsen PM.

Cancer Res. 2014 Feb 1;74(3):921-31. doi: 10.1158/0008-5472.CAN-13-2424. Epub 2013 Dec 13.

38.

A systematic review of surgical biopsy for LCIS found at core needle biopsy - do we have the answer yet?

Buckley ES, Webster F, Hiller JE, Roder DM, Farshid G.

Eur J Surg Oncol. 2014 Feb;40(2):168-75. doi: 10.1016/j.ejso.2013.10.024. Epub 2013 Nov 6. Review.

PMID:
24246610
39.

Do breast cancer risk factors differ among those who do and do not undertake mammography screening?

Beckmann KR, Roder DM, Hiller JE, Farshid G, Lynch JW.

J Med Screen. 2013 Dec;20(4):208-19. doi: 10.1177/0969141313510293. Epub 2013 Oct 23.

PMID:
24153439
40.

Impact of hormone replacement therapy use on mammographic screening outcomes.

Beckmann KR, Farshid G, Roder DM, Hiller JE, Lynch JW.

Cancer Causes Control. 2013 Jul;24(7):1417-26. doi: 10.1007/s10552-013-0221-1. Epub 2013 May 7.

PMID:
23649232
41.

Sentinel node biopsy and large (≥3 cm) breast cancer.

Beumer JD, Gill G, Campbell I, Wetzig N, Ung O, Farshid G, Uren R, Stockler M, Gebski V.

ANZ J Surg. 2014 Mar;84(3):117-20. doi: 10.1111/ans.12139. Epub 2013 Apr 18.

PMID:
23601070
42.

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.

Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, Fox SB, Francis GD, Waite B, McCue G, Raymond WA, Robbins PD, Farshid G.

Breast Cancer Res Treat. 2012 Jul;134(2):617-24. doi: 10.1007/s10549-012-2093-6. Epub 2012 Jun 8.

43.

Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.

Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A.

Am J Surg Pathol. 2012 Apr;36(4):577-82. doi: 10.1097/PAS.0b013e318244adbb.

PMID:
22314190
44.

Independent predictors of breast malignancy in screen-detected microcalcifications: biopsy results in 2545 cases.

Farshid G, Sullivan T, Downey P, Gill PG, Pieterse S.

Br J Cancer. 2011 Nov 22;105(11):1669-75. doi: 10.1038/bjc.2011.466. Epub 2011 Nov 3.

45.

Multiplex ligation-dependent probe amplification for HER2 testing in breast cancer.

Farshid G.

Expert Rev Mol Diagn. 2011 Nov;11(8):767-9. doi: 10.1586/erm.11.68. No abstract available.

PMID:
22022937
46.

An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition.

Gregory PA, Bracken CP, Smith E, Bert AG, Wright JA, Roslan S, Morris M, Wyatt L, Farshid G, Lim YY, Lindeman GJ, Shannon MF, Drew PA, Khew-Goodall Y, Goodall GJ.

Mol Biol Cell. 2011 May 15;22(10):1686-98. doi: 10.1091/mbc.E11-02-0103. Epub 2011 Mar 16.

47.

Validation of the multiplex ligation-dependent probe amplification (MLPA) technique for the determination of HER2 gene amplification in breast cancer.

Farshid G, Cheetham G, Davies R, Moore S, Rudzki Z.

Diagn Mol Pathol. 2011 Mar;20(1):11-7. doi: 10.1097/PDM.0b013e3181ed7832.

PMID:
21326034
48.

Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice.

Farshid G, Armes JE, Bell R, Cummings M, Fox S, Francis G, Haswell M, Morey A, McCue G, Raymond W, Robbins P, Bilous M.

Diagn Mol Pathol. 2010 Dec;19(4):187-93. doi: 10.1097/PDM.0b013e3181e1cc9d.

PMID:
21052003
49.

Familial concordance of breast cancer pathology as an indicator of genotype in multiple-case families.

Balleine RL, Provan PJ, Pupo GM, Pathmanathan N, Cummings M, Farshid G, Salisbury EL, Bilous AM, Byth K; KConFab Investigators, Mann GJ.

Genes Chromosomes Cancer. 2010 Dec;49(12):1082-94. doi: 10.1002/gcc.20816.

PMID:
20815029
50.

Predictors of malignancy in screen-detected breast masses with indeterminate/equivocal (grade 3) imaging features.

Farshid G, Walker A, Battersby G, Sullivan T, Gill PG, Pieterse S, Downey P.

Breast. 2011 Feb;20(1):56-61. doi: 10.1016/j.breast.2010.07.002. Epub 2010 Aug 9.

PMID:
20691591

Supplemental Content

Loading ...
Support Center